Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in newly diagnosed pulmonary TB patients in Tanzania

Denti, Paolo; Jeremiah, Kidola; Chigutsa, Emmanuel; Faurholt-Jepsen, Daniel; PrayGod, George; Range, Nyagosya; Castel, Sandra; Wiesner, Lubbe; Hagen, Christian Munch; Christiansen, Michael; Changalucha, John; McIlrion, Helen; Friis, Henrik; Andersen, Åse Bengård

Published in:
P L o S One

DOI:
10.1371/journal.pone.0141002

Publication date:
2015

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Denti, P., Jeremiah, K., Chigutsa, E., Faurholt-Jepsen, D., PrayGod, G., Range, N., ... Andersen, Å. B. (2015). Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in newly diagnosed pulmonary TB patients in Tanzania. DOI: 10.1371/journal.pone.0141002
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania

Paolo Denti1, Kidola Jeremiah2,3*, Emmanuel Chigutsa1, Daniel Faurholt-Jepsen4, George PrayGod3, Nyagosya Range5, Sandra Castel1, Lubbe Wiesner1, Christian Munch Hagen6, Michael Christiansen6, John Changalucha3, Helen McIleron1, Henrik Friis4, Aase Bengaard Andersen2,7

1 Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa, 2 Department of Infectious Diseases, Odense University Hospital, Odense, Denmark, 3 National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania, 4 Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark, 5 National Institute for Medical Research, Muhimbili Research Centre, Dar Es Salaam, Tanzania, 6 Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark, 7 Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark

☯ These authors contributed equally to this work.
¤ Current Address: Eli Lilly and Company, Indianapolis, Indiana, United State of America
*
jkidola@gmail.com

Abstract

Exposure to lower-than-therapeutic levels of anti-tuberculosis drugs is likely to cause selection of resistant strains of Mycobacterium tuberculosis and treatment failure. The first-line anti-tuberculosis (TB) regimen consists of rifampicin, isoniazid, pyrazinamide, and ethambutol, and correct management reduces risk of TB relapse and development of drug resistance. In this study we aimed to investigate the effect of standard of care plus nutritional supplementation versus standard care on the pharmacokinetics of isoniazid, pyrazinamide and ethambutol among sputum smear positive TB patients with and without HIV. In a clinical trial in 100 Tanzanian TB patients, with or without HIV infection, drug concentrations were determined at 1 week and 2 months post initiation of anti-TB medication. Data was analysed using population pharmacokinetic modelling. The effect of body size was described using allometric scaling, and the effects of nutritional supplementation, HIV, age, sex, CD4+ count, weight-adjusted dose, NAT2 genotype, and time on TB treatment were investigated. The kinetics of all drugs was well characterised using first-order elimination and transit compartment absorption, with isoniazid and ethambutol described by two-compartment disposition models, and pyrazinamide by a one-compartment model. Patients with a slow NAT2 genotype had higher isoniazid exposure and a lower estimate of oral clearance (15.5 L/h) than rapid/intermediate NAT2 genotype (26.1 L/h). Pyrazinamide clearance had an estimated typical value of 3.32 L/h, and it was found to increase with time on treatment, with a 16.3% increase after the first 2 months of anti-TB treatment. The typical clearance of ethambutol was estimated to be 40.7 L/h, and was found to decrease with age, at a rate of 1.41%
per year. Neither HIV status nor nutritional supplementations were found to affect the pharmacokinetics of these drugs in our cohort of patients.

Introduction

The aim of anti-tuberculosis (TB) treatment is to provide a safe, effective, and fast acting therapy [1]. Isoniazid, pyrazinamide, and ethambutol constitute important companion drugs used in a standard first-line short-course regimen together with rifampicin [2] and are believed to eradicate aerobic, anaerobic, microaerophilic, and drug tolerant persisting bacteria [3]. While isoniazid and pyrazinamide have bactericidal activity against \( M. \) \( \text{tuberculosis} \), ethambutol is considered a bacteriostatic drug, though it may have bactericidal activity when given in higher doses [2]. Treatment success rates of 88% were reported in Tanzania in 2011 using this regimen, thereby meeting the 85% target set by the World Health Assembly in 1993 [4, 5]. However, multidrug-resistance (MDR-TB) is emerging (1.1% of newly diagnosed TB cases in Tanzania are MDR-TB) and may over time threaten the standard first-line regimen [4, 5]. Previous studies have shown that low plasma anti-TB drug concentrations may result in treatment failure [6, 7] and low plasma concentrations of rifampicin and isoniazid have been associated with MDR-TB [8, 9]. Wide variability is reported in the pharmacokinetics (PK) of isoniazid, pyrazinamide, and ethambutol [10–12], with factors such as age and HIV status and antiretroviral treatment (ART) possibly affecting TB drug concentrations [12–17]. Furthermore, malnutrition also seems to affect drug exposure by decreasing total clearance and increasing plasma half-life [18]. Nutritional rehabilitation of children with kwashiorkor has been reported to enhance isoniazid clearance [19], but the influence of administering nutritional supplementation to adult TB patients is unclear. We therefore conducted a randomized clinical trial in Mwanza, Tanzania to examine the effect of nutritional supplementation on the pharmacokinetics of first-line anti-TB drugs in a cohort of pulmonary TB patients with and without HIV. We recently reported the positive effect on a nutritional supplementation on rifampicin exposure in the HIV co-infected patients (all ART naïve) [20]. In this analysis we aimed to investigate the effect of standard of care plus nutritional supplementation vs. standard care on PK of isoniazid, pyrazinamide, and ethambutol among sputum smear positive TB patients with and without HIV. We also explored the effect of other covariates, including NAT2 genotype on the PK of isoniazid.

Materials and Methods

Ethics Statement

Ethical permission to conduct the study was granted by the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR) in Tanzania. Oral and written information were provided in Swahili to all participants prior to obtaining informed oral and written consent. Written consent was obtained from parents/legal guardians of participants aged 15–17 years.

Study design, setting, and participants

The study was an open-label randomized clinical trial (ClinicalTrials.com: ISRCTN 16552219) among 100 sputum smear positive TB patients, and details about the protocol are available as supplementary information) (S1 Protocol). The study was conducted in the city of
Mwanza, Tanzania between September 2010 and August 2011. Mwanza is the second largest city in the country and is the region with the second highest number of TB case notification (9.3%) after Dar es Salaam (21.9%) [5]. The study recruited newly diagnosed sputum positive pulmonary TB patients aged 15 years or above. HIV-infected patients on ART, pregnant women, critically ill patients not likely to survive > 48 hours, and non-residents of Mwanza City were excluded.

**TB medication and intervention**

The TB patients were administered TB medication according to the National Tuberculosis and Leprosy Programme (NTLP) treatment guidelines [5], and those found co-infected with HIV were managed according to National guidelines for the management of HIV and AIDS policy [21]. The anti-TB drugs prescribed were formulated in fixed-dose combination (FDC) tablets containing isoniazid (75 mg), rifampicin (150 mg), pyrazinamide (400 mg), and ethambutol (275 mg) (Sandoz Pvt Ltd, India). Dosing was adjusted based on body weight: 3 tablets for patients weighing up to 50 kg, and 4 tablets for those weighing more than 50 kg. The patients were randomized to either receive or not receive nutritional supplementation in the form of biscuits (Compact A/S, Bergen, Norway) containing high-energy (1000 kcal) and vitamin/minerals according to trial protocol [20]. A complete list of nutrients content is shown in Table 1.

**Data collection**

A standardised questionnaire was used to solicit demographic characteristics, previous TB history, and use of alcohol. Anthropometric measurements including weight and height were obtained at each visit. All participants had a chest x-ray taken at recruitment and two independent radiographers confirmed abnormalities.

**Laboratory analyses**

At recruitment, venous blood samples were collected. CD4+ lymphocyte count was analysed using a Coulter® Epics XL-MCL™ Flow Cytometer (Beckman Coulter, Brea, CA).

| Table 1. Nutrients composition of the intervention used in the trial. |
|---------------------------------------------------------------|
| **1 daily biscuit with the following micro nutrients**          |
| Vitamin A (5000 IU)                                          |
| Vitamin B1 (20 mg)                                           |
| Vitamin B2 (20 mg)                                           |
| Vitamin B6 (25 mg)                                           |
| Vitamin B12 (50 mg)                                          |
| Folic acid (0.8 mg)                                          |
| Niacin (40 mg)                                               |
| Vitamin C (200 mg)                                           |
| Vitamin E (60 mg)                                            |
| Vitamin D3 (200 IU)                                          |
| Selenium 0.2 mg                                              |
| Copper (5 mg)                                                |
| Zinc (30 mg)                                                 |
| Plus 4 additional daily biscuit with energy-protein          |

*Duration of intervention 60 days

doi:10.1371/journal.pone.0141002.t001
Haemoglobin level and white blood cell counts were analysed using haematological Coulter AcT 5 diff, (Beckman Coulter, Brea, CA). HIV status was determined on two rapid tests done in parallel (SD Bioline HIV-1/2 3.0, Standard Diagnostics Inc., Kyonggi-do, South Korea; Determine HIV-1/HIV-2, Inverness Medical Innovations Inc., Delaware, USA). Discordant HIV test results were resolved using HIV UNIFORM II ELISA (Organon Teknia Ltd, Boxtel, Netherlands).

Pharmacokinetic plasma sample collection, processing and analysis

Patients were scheduled for plasma sample collection on two occasions: at one week and two months post-initiation of anti-TB medication. One day before blood sampling patients were instructed to fast overnight, and on the morning of the PK visit, the study nurse administered the anti-TB drugs according to body weight. Whole blood was collected in 5 mL of lithium heparin tubes at 2, 4, and 6 hours post-dose. Samples were immediately centrifuged at 3000 rpm for 10 min to separate the plasma and transferred to -80°C within 30 minutes. The plasma samples were then transported in dry ice to the Division of Clinical Pharmacology, University of Cape Town, South Africa, for determination of isoniazid, pyrazinamide, and ethambutol concentrations using validated tandem mass spectrometry high-performance liquid chromatography (LC-MS/MS) methods. An AB Sciex API mass spectrometer was operated in the multiple reactions monitoring (MRM) mode. The assays were validated over the concentration range of 0.112 to 26 mg/L for isoniazid, 0.203 to 81.1 mg/L for pyrazinamide and 0.081 to 5.18 mg/L for ethambutol. The mean percentage accuracies during inter-day sample analysis at low, medium, and high quality control levels, respectively, were 98.2%, 99.3%, and 94.7% for isoniazid, 97.8%, 102.1%, and 100.5% for pyrazinamide, and 99%, 101.3%, and 99.6% for ethambutol. The precision coefficient of variation for determination at low, medium, and high quality control level for both pyrazinamide and ethambutol was less than 4% and for isoniazid less than 5%. Concentrations below the validation range of the assay were reported as below the lower limit of quantification (BLQ).

DNA extraction and NAT2 analysis

Serum aliquots for N-acetyltransferase-2 (NAT2) genotype were kept under -80°C until analyzed. Genotyping was carried out at the Statens Serum Institut, Copenhagen, DK after DNA was extracted from blood using QIAamp DNA minikit (Qiagen GmbH, Hilden, Germany). An annealing temperature of 60°C was used in all polymerase chain reactions (PCR). The PCR products were sequenced using BigDye Terminator v1.1 Cycle Resequencing (ABI), and analyzed on an ABI3730 DNA Analyzer. The resulting sequences were compared to NCBI accession no. NG_012246.1 N-acetyltransferase-2 (NAT2) using Sequencer 5.0 software (Gene Codes, Ann Arbor, USA). NAT2 haplotypes were based on dbSNP IDs: c.282C>T (rs1041983), c.341T>C (rs1801280), c.481C>T (rs1799929), c.590G>A (rs1799930), c.803A>G (rs1208) and c.857G>A (rs1799931) and the acetylator phenotype was inferred using NAT2PRED (http://nat2pred.rit.albany.edu/).

Nonlinear mixed-effects modelling analysis

Nonlinear mixed-effects modelling was employed to interpret the data with the software NONMEM 7.3 [22], and the algorithm First-Order Conditional Estimation with eta-epsilon interaction. Pirana, Perl-speaks-NONMEM, and xpose4 were used to aid the modelling process and prepare model diagnostics [23]. The modelling procedure was similar for all drugs, as outlined below. Several structural models were tested: one- and two-compartment disposition kinetics with first-order elimination and several approaches for absorption: first-order, lagged first-
order and transit compartment absorption [24]. The statistical model assumed log-normal distribution for the between-subject and occasion random effects, and a combined additive and proportional structure for the residual unexplained variability, with the additive component of the error bound to be at least 20% of the lower limit of quantification (LLOQ). Allometric scaling with either total body weight (WT) or fat-free mass (FFM) was applied to all clearances (CL and Q) and volumes of distribution (Vc and Vp), as advocated by Anderson and Holford [25]. The effect of other covariates was tested and included in the model based on significant decreases ($p<0.05$) in the Objective Function Value (OFV) and physiological plausibility. Covariates tested for effects on PK parameters were: HIV co-infection, nutritional supplementation, age, sex, CD4+ lymphocyte count, daily weight-adjusted dose, and time on TB treatment. Additionally, NAT2 acetylator status was tested on isoniazid PK. The OFV, goodness of fit plots, and Visual Predictive Checks (VPC) guided model development. The robustness of the final parameter estimates was assessed with a non-parametric bootstrap. The post-hoc individual parameter estimates from the final model were used to obtain the exposure parameters $C_{\text{max}}$ and $\text{AUC}_{0-24}$. These individual values were calculated to provide summary values for comparison with previous studies, but they were not used with the purpose of statistical inference, since they are dependent on the model and they are affected by statistical shrinkage (especially $C_{\text{max}}$)[26].

Results

A total of 100 newly diagnosed pulmonary TB patients were enrolled in the study (Fig 1). The sex and HIV status distributions were almost even, with 42% ($n=42$) women and 50 HIV co-infected. The median (IQR) age was 35 years (29; 40) and weight was 51.9 kg (48.2; 57.3). As many as 48 subjects were classified as NAT2 slow acetylators, 48 as intermediate, and 2 as rapid acetylators, while the acetylator status of 2 subjects could not be determined. Baseline characteristics are shown in Table 2.

A total of 192 isoniazid PK profiles were obtained from 100 patients, based on 574 plasma concentration measurements, three of which were BLQ. The final structural model was a two-compartment disposition with transit compartment absorption. The data did not support significantly different estimates for the absorption rate constant ($k_a$) and for the rate constants between the transit compartments ($k_{tr}$), so the absorption model was simplified. Fat-free mass (FFM) was found to be the most suitable size descriptor for allometric scaling. The model supported between-subject variability in clearance and between-occasion variability in bioavailability and mean absorption transit time (MTT). The population pharmacokinetic final parameter estimates are shown in Table 3, and a visual predictive check is shown in Fig 2. The model detected a significant effect of NAT2 acetylator status on CL (51.4 points improvement in OFV, $p<10^{-6}$). Subjects with slow NAT2 genotype had a lower clearance (15.5 L/h) compared to rapid or intermediate NAT2 (26.1 L/h). For the two subjects with undetermined NAT2 acetylator status, their values were imputed using a mixture model taking into account both their observed isoniazid concentrations and the relative frequency of each genotype in the rest of the study population, as suggested in Keizer et al. [27]. The model did not detect significant effects of HIV or nutritional supplementation on clearance or bioavailability. The individual values of $C_{\text{max}}$ and $\text{AUC}_{0-24}$, stratified by NAT2 genotype are shown in Fig 3. Among the slow NAT2 acetylators, median $\text{AUC}_{0-24}$ and $C_{\text{max}}$ were 17.1 h-mg/L (IQR: 14.7; 21.2) and 3.53 mg/L (IQR: 3.09; 3.83), respectively. The subjects categorised as rapid or intermediate NAT2 acetylators achieved lower median $\text{AUC}_{0-24}$ and $C_{\text{max}}$: 9.89 h-mg/L (IQR: 7.99; 12.1) and 3.03 mg/L (IQR: 2.76; 3.49), respectively.
For pyrazinamide and ethambutol, only 116 PK profiles from 98 patients based on 346 plasma concentrations, were included in the PK modelling. Since many patients had already been switched to the continuation phase of treatment, comprised only of isoniazid and rifampicin, at the time of the second PK visit, the number of analysed patients is lower than for the isoniazid studies (n = 18). No plasma concentrations were BLQ.

For pyrazinamide, the best model was a one-compartment disposition, first-order elimination, and transit compartment absorption with no separate estimate of absorption rate constants ($k_{\text{transit}} = k_a$). The final parameter estimates are included in Table 4, while a visual predictive check is shown in Fig 4. The best size predictor for allometric scaling of clearance was total body weight, while volume of distribution was better scaled with fat-free mass.
Table 2. Baseline characteristics of 100 pulmonary sputum smear positive patients starting TB treatment.

| Characteristics                  | Values\(^a\)       |
|----------------------------------|--------------------|
| Age (years)                      | 35 (29; 40)        |
| Sex (Males)                      | 58 (58.0)          |
| Weight (kg)                      | 51.9 (48.3; 57.3)  |
| Body mass index (kg/m\(^2\))    | 18.8 (17.3; 19.9)  |
| Haemoglobin (g/dL)\(^b\)        | 111 (93; 125)      |
| White blood cell (x 10\(^9\)/L)\(^b\) | 6.6 (4.6; 9.1)     |
| CD4+ count (cell/\(\mu\)L)\(^b\) | 375 (160; 642)     |
| HIV infected                     | 50 (50.0)          |
| TB cavitations present           | 28 (32.2)          |
| Fasting blood glucose (mmol/L)   | 6 (5.4; 6.6)       |
| Nutritional supplementation      |                    |
| No Supplementation               | 49 (49.0)          |
| Received supplementation         | 51 (51.0)          |
| NAT2 phenotype                   |                    |
| Slow                             | 48(48.0)           |
| Intermediate                     | 48 (48.0)          |
| Rapid                            | 2 (2.0)            |
| Unknown                          | 2 (2.0)            |

\(^a\)Data are median (IQR) or n (%).
\(^b\)The total number of observations was not 100 due to missing values.

doi:10.1371/journal.pone.0141002.t002

Table 3. Isoniazid pharmacokinetics parameter estimates among newly diagnosed sputum smear positive TB patients.

| Parameter description                                      | Typical value |
|------------------------------------------------------------|---------------|
| Clearance for rapid/intermediate NAT2 acetylators\(^a\) (L/h) | 26.1 (23.6; 29.5) |
| Clearance for slow NAT2 acetylators\(^a\) (L/h)             | 15.5 (14.3; 16.7) |
| Central volume of distribution\(^a\) - Vc (L)              | 48.2 (18.7; 56.4) |
| Inter-compartmental clearance\(^a\) Q (L/h)                | 16.1 (7.5; 61.6)  |
| Peripheral volume\(^a\) Vp (L)                             | 16.5 (12.4; 45.4) |
| Mean transit time “MTT” (h)                                | 0.924 (0.78; 1.33) |
| Number of transit compartment—“NN”                         | 2.73 (1.15; 5.49) |
| Bioavailability—“F”\(^c\)                                  | 1 FIXED        |
| Proportional error (%)                                     | 13.3 (11.7; 14.4) |
| Additive error (mg/L)                                      | 0.0224 FIXED   |
| Between subject variability of clearance\(^b\) (%CV)       | 30.7 [6%] (24.8; 35.5) |
| Between occasion variability of mean transit time\(^b\) (%CV) | 37.4 [29%] (25.8; 41.7) |
| Between occasion variability of bioavailability\(^b\) (%CV) | 12.8 [79%] (11.1; 15.7) |

\(^a\)Allometric scaling was used for CL, Vc, Q, and Vp, so the typical values are reported for the median fat-free mass of the cohort (43 kg)

\(^b\)The between-subject and—occasion variability was assumed log-normally distributed and is reported here as approximate %CV. In square brackets, the value of shrinkage.

\(^c\)The precision of the estimates was obtained with a non-parametric 90% confidence interval based on a 500 sample bootstrap.

doi:10.1371/journal.pone.0141002.t003
Pyrazinamide clearance increased with time on treatment: the model estimated 16.3% faster clearance from the data collected after more than 18 days of treatment (Δ-6.96 OFV, p < 0.01). This break point was chosen to include all PK profiles from the second PK visit, mostly collected 2 months after treatment initiation, plus two late-comers for the first PK occasion (on days 19 and 26). Other factors including HIV status, nutritional supplementation, age, sex, CD4 count, and weight-adjusted dose were tested in the model, but did not significantly influence pyrazinamide PK. The relationship between these individual values of pyrazinamide exposure and time on TB treatment is shown in Fig 5. Among the PK profiles obtained in the first 2 weeks of TB treatment, median pyrazinamide AUC₀-2₄ and Cₘₐₓ were 413 h·mg/L (IQR: 337; 546) and 37.8 mg/L (IQR: 32.8; 44.5), respectively. For the profiles collected after 2 weeks of TB treatment AUC₀-2₄ and Cₘₐₓ decreased to 364 h·mg/L (IQR: 277; 433) and 32.4 mg/L (IQR: 30.9; 37.5), respectively.

For ethambutol, the best-fitting model was a two-compartment disposition, with first-order elimination, and transit compartment absorption with no separate estimate of kₐ. The final parameter estimates are shown in Table 5 and a visual predictive check is shown in Fig 6. Although the inclusion of two-compartment disposition kinetics significantly improved the model fit (Δ-30 points OFV), the parameter estimates for the volume of the peripheral
compartment (Vp) and the inter-compartmental clearance (Q) proved unstable. To stabilise the model while allowing the inclusion of the two-compartment kinetics, a prior was included [28], based on parameter estimates from a PK model of ethambutol developed on data from a similar population of TB patients [29]. After applying allometric scaling to adjust for differences in body weight amongst the studies, the typical values for the priors of Vp and Q were 420.7 L/h and 64.4 L/h, respectively. The priors were assumed to have a Gaussian distribution around these typical values, and were included in the model imputing a large uncertainty (50% CV) to make them weakly informative. Testing different settings for the prior distributions showed that the estimates of the other parameters in the model were not significantly affected. After the inclusion of the priors, the two-compartment model proved stable and provided a significantly better fit than the one-compartment model, and was used for the analysis. The best predictor for allometric scaling of all clearance and volume parameters was total body weight. Additionally, older age was associated with lower clearance, with every year of age causing a

Fig 3. Box and whisker plots showing isoniazid exposure vs. time NAT2 acetylator status (grouped as rapid or intermediate together vs. slow). The left panel displays AUC_{0-24} and the right panel C_{max}. The dots represent individual values. Since for most subjects 2 PK profiles were available, geometric mean was used to summarize the individual values.

doi:10.1371/journal.pone.0141002.g003
decrease of 1.41% in clearance (-23.4 OFV, p < 10\(^{-5}\)). No other factors tested in the model, including HIV status, nutritional supplementation, sex, CD4 count, and time on TB treatment, significantly affected the PK. The relationship between the individual values of ethambutol exposure and age is shown in Fig 7. Median ethambutol AUC\(_{0-24}\) was 23.6 h·mg/L (IQR: 20.5; 28.9) and C\(_{\text{max}}\) was 2.44 mg/L (IQR: 2.09; 2.86).

### Discussion

We studied the effect of nutritional supplementation and HIV status on the pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pulmonary TB patients during the intensive phase of a standard course of TB treatment.

Malnutrition is a well-known companion to both HIV and TB, and food programs are therefore being launched in many Sub-Saharan regions to alleviate this problem. Nutritional supplementation has previously been reported to improve treatment outcome in both TB and HIV patients [30, 31], so our study aimed to investigate if nutritional intervention is affecting the PK exposure of the first-line TB drugs. We recently published the beneficial effect of nutritional supplementation on rifampicin exposure, especially in HIV positive TB patients [20]. In the current study, we found that nutritional supplementation had no effect on isoniazid, pyrazinamide, and ethambutol exposure, and there was no effect of HIV co-infection. The effect of nutritional supplements may depend on the individual’s baseline micronutrients status and only cause an effect in undernourished subjects [32]. In our cohort, baseline BMI was 18.8

| Parameter description                     | Typical value     |
|-------------------------------------------|-------------------|
| Clearance\(^a\)–CL (L/h)                 | 3.32 (3.10; 3.53) |
| Volume of distribution\(^a\)–V\(_d\) (L)  | 40.1 (38.4; 42.1) |
| Absorption mean transit time—“MTT” (h)   | 0.84 (0.42; 1.08) |
| Number of absorption transit compartments–NN | 2.6 (0.2; 7.3)  |
| Bioavailability–F                        | 1 FIXED           |
| Clearance change after 2 months of treatment\(^b\) (+%) | 16.3 (2.6; 29.2) |
| Proportional error (%)                   | 7.2 (6.0; 8.1)    |

\(^a\)Allometric scaling was used for clearance (total weight) and volume of distribution (fat-free mass), so the values are reported for the median weight (52 kg) and fat-free mass (43 kg) of the cohort.

\(^b\)Although nearly all the profiles with increased clearance were collected at ~2 months after TB treatment initiation, the cut-off used in the model was 18 days.

\(^c\)The between-subject and–occasion variability was assumed log-normally distributed and is reported here as approximate %CV. In square brackets, the value of shrinkage.

\(^d\)The precision of the estimates was obtained with a non-parametric 90% confidence interval based on a 500-sample bootstrap.

doi:10.1371/journal.pone.0141002.t004

decrease of 1.41% in clearance (-23.4 OFV, p < 10\(^{-5}\)). No other factors tested in the model, including HIV status, nutritional supplementation, sex, CD4 count, and time on TB treatment, significantly affected the PK. The relationship between the individual values of ethambutol exposure and age is shown in Fig 7. Median ethambutol AUC\(_{0-24}\) was 23.6 h·mg/L (IQR: 20.5; 28.9) and C\(_{\text{max}}\) was 2.44 mg/L (IQR: 2.09; 2.86).
We further assessed predictors that potentially could influence the PK, including the NAT2 genotype, age of the patient, and timing of the sampling with respect to treatment initiation. The NAT2 gene product is expressed in the liver and small intestine, constituting an important phase II enzyme responsible for acetylating isoniazid [33]. NAT2 activities may vary due to differences in the NAT2 alleles or haplotypes caused by Single-Nucleotide Polymorphisms (SNPs) [33]. As expected, NAT2 genotype strongly influenced isoniazid pharmacokinetics. Patients categorized as slow NAT2 acetylators had a lower clearance (typical value 15.5 vs. 26.1 L/h) and higher estimated isoniazid exposures (AUC0-24 of 17.1 vs. 9.89 h·mg/L) compared to rapid or intermediate NAT2 acetylators. The distribution of NAT2 genotypes is comparable to what was found by Sabbagh et al. and Matimba et al. who reported a high prevalence of slow and intermediate acetylators in African populations, due to the common NAT2*5, *6, and *14 polymorphisms [34, 35]. Our findings are in line with those reported by Conte et al. examining the effects of gender, AIDS, and acetylator status on the steady-state concentrations of orally administered isoniazid in plasma and lungs [36]. Similar findings were reported by Chen et al. assessing the influence of NAT2 genotype on the plasma concentration of isoniazid and acetyl-

![Fig 4. Visual predictive check (VPC) for pyrazinamide concentration versus time, stratified by time on TB treatment. The circles represent the original data, the dashed and solid lines are the 5th, 50th, and 95th percentiles of the original data, while the shaded areas are the corresponding 95% confidence intervals for the same percentiles, as predicted by the model.](doi:10.1371/journal.pone.0141002.g004)

(IQR 17.3; 19.9) which classifies most of the participants in the category of underweight; however, we did not assess their micronutrient status.

Pharmacokinetics of INH PZA and EMB in TB Patients
isoniazid in a Chinese population [37]. Pasipanodya et al. have compiled these results in a meta-analysis and suggest that this genetic variability is a contributing factor for microbiological treatment failure [9].

When characterising pyrazinamide PK, we found that clearance increases with time on treatment, an observation also recently reported by Chirehwa et al. in South African TB patients co-infected with HIV [38]. They detected an increase of 19% in clearance by day 28 after treatment initiation, which is comparable with our finding of a 16.3% increase. During TB treatment, pyrazinamide is given concomitantly (or even co-formulated) with rifampicin, which is a well-known potent inducer of hepatic and intestinal CYP3A subfamily and many other metabolic pathways via activation of the pregnane X-receptor (PXR) [39]. For this reason, rifampicin exposure results in increasing clearance of many co-administered drugs, and it could be speculated that rifampicin may induce microsomal deamidase or some other pathway, thus enhancing pyrazinamide clearance [38]. On the other hand, the observed increase in clearance could also be the effect of the overall improvement in health conditions of the patients.
after treatment initiation. The pyrazinamide exposures we observed did not significantly deviate from previous results [40–44]. In the current study, the estimates for median pyrazinamide C\text{max} and AUC\text{0-24} were in line with previous reports showing median C\text{max} levels ranging from 27 to 38 mg/L and AUC\text{0-24} between 321 and 418 h/L [41–44]. Our results also confirm the reports by Fahimi et al. and Tappero et al. who showed that the majority of patients achieve pyrazinamide plasma exposures within a range relatively narrower than other TB drugs, due to its efficient absorption [45, 46]. Pasipanodya et al. recently investigated the TB drug concentration levels that are predictive of TB treatment outcome, and they reported that pyrazinamide peak concentration C\text{max} = 32.4 mg/L, while the median pyrazinamide AUC\text{0-24} at around 2 months after treatment initiation was 364 h·mg/L, and a similar value is obtained when adjusting the median AUC\text{0-24} observed after 1 week to account for the estimated increase in clearance, i.e., multiplying by 1/(1+16.3%). More specifically, we found that 31.6% of this population had pyrazinamide AUC\text{0-24} ≤ 363 h·mg/L around 1 week and 55.6% at around 2 months after TB treatment initiation. This means that about half of the patients in our cohort achieved exposures below the proposed AUC threshold, and nearly none achieved

Table 5. Ethambutol pharmacokinetics parameter estimates among newly diagnosed sputum smear positive pulmonary TB patients.

| Parameter description                                      | Typical value                  |
|------------------------------------------------------------|--------------------------------|
| Clearancena–b – CL (L/h)                                   | 40.7 (35.7; 45.2)              |
| Central volume of distributionna – Vc (L)                  | 266 (207; 326)                 |
| Inter-compartmental clearancea–c – Q (L/h)                | 109 (82; 136)                  |
| Peripheral volume of distributiona–c – Vp (L)             | 687 (493; 850)                 |
| Absorption mean transit time—“MTT” (h)                    | 2.54 (2.32; 2.78)              |
| Number of absorption transit compartments—NN              | 11.1 (6.0; 30.2)               |
| Bioavailability–F                                         | 1 FIXED                        |
| Effect of age on Clearancen (%) change per year            | -1.41 (-1.76; -1.09)           |
| Proportional error (%)                                     | 22.5 (19.1; 24.5)              |
| Additive error (mg/L)                                      | 0.0162 FIXED                   |
| Between-subject variability in bioavailabilityn (%CV)      | 21.5 [14%] (15.7; 26.2)        |
| Between-occasion variability in mean transit timen (%CV)   | 26.1 [14%] (16.9; 33.7)        |

\( ^a \)Allometric scaling was used for CL, Vc, Q, and Vp, so the values are reported for the median weight of the cohort (52 kg).

\( ^b \)CL was affected by age, the typical value reported here refers to the median age in the cohort (35 years)

\( ^c \)Q and Vp were estimated using Gaussian priors with typical values 64.4 L/h and 420.7 L respectively, and 50% uncertainty.

\( ^d \)The between-subject and—occasion variability was assumed log-normally distributed and is reported here as approximate %CV. In square brackets, the value of shrinkage.

\( ^e \)The precision of the estimates was obtained with a non-parametric 90% confidence interval based on a 500 sample bootstrap
C_{\text{max}} above the cut-off. Unfortunately, our study was not powered to assess the long-term effect of drug exposure on treatment outcome.

Ethambutol plasma concentrations among our study participants were relatively low compared with previous studies [10, 40–42, 44], reporting median $C_{\text{max}}$ ranging from 2.7 to 4.8 mg/L and median AUC_{0-24} between 20 and 47 h·mg/L. In our cohort, median ethambutol $C_{\text{max}}$ was 2.44 mg/L and AUC_{0-24} was 23.6 h·mg/L, values similar to those reported by Tappero et al. and Um et al. [46, 47]. Ethambutol pharmacokinetics has been previously associated with many factors including malnutrition, HIV infection, age, and sex [12, 42, 48–50]. In our cohort, age was found to affect ethambutol clearance, with increasing age leading to lower clearance at a decrease rate of 1.41% per year. A relationship between age and anti-TB drug plasma levels has been previously reported in a study in South African patients [12], where it was suggested that older patients have higher levels of ethambutol and isoniazid because of the functional decrease of metabolic pathways and reduced renal clearance capacity. HIV infection was not found to affect ethambutol plasma concentration in this population, in contrast to studies by Zhu et al. [51] and Jonsson et al. [10], who both reported that HIV infection was associated with a reduction in ethambutol concentrations.

**Fig 6. Visual predictive check (VPC) for ethambutol concentration versus time.** The circles represent the original data, the dashed and solid lines are the 5th, 50th, and 95th percentiles of the original data, while the shaded areas are the corresponding 95% confidence intervals for the same percentiles, as predicted by the model.

doi:10.1371/journal.pone.0141002.g006
Limitations and strengths

The number of PK samples collected at each visit was small, limiting the characterization of the pharmacokinetic curve, as well as the precision of the individual estimates of exposure, especially $C_{\text{max}}$. This was a compromise accepted in the study design to limit the time patients had to spend at the clinic during PK sampling, as the patients involved were treated as outpatients. The data was interpreted with nonlinear mixed-effects modelling, which appropriately handles sparse sampling and supports the robustness of our findings.

Another limitation of the study is represented by the few PK profiles of pyrazinamide and ethambutol available from the second visit (only 18 out of those that came back for the second evaluation), since a majority of the patients had already been switched to the continuation phase not including pyrazinamide and ethambutol. This missingness of the data reduced the sample size for the investigation of the effect of the time on treatment, but nonlinear mixed-effects modelling appropriately handles sparse sampling and supports the robustness of our findings.

Fig 7. In the left panels, scatter plots showing ethambutol exposure vs. patient age. In the right small panels, box and whiskers plots summarizing the same values. The top panels refer to $\text{AUC}_{0-24}$ and the bottom panels to $C_{\text{max}}$. For all patients for whom 2 PK profiles were available, geometric mean was used to obtain summary values.

doi:10.1371/journal.pone.0141002.g007
effects modelling is known to handle these kinds of scenarios well. Moreover, the two cohorts (patients in continuation vs intensive phase at PK visit 2) had similar demographic characteristics and similar proportions of HIV infection and subjects randomised to supplementation (data not shown).

This study was initiated and conducted before clear policies regarding the timing of ART to HIV co-infected TB patients were established. Therefore pharmacologic interaction with various ARTs is not an issue in this study.

Conclusions
In summary, we reported the pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in a cohort of Tanzanian TB patients. We found that nutritional supplements with energy-protein plus micronutrients given to TB patients during the intensive phase of a conventional TB regimens have no effect on the exposure of isoniazid, pyrazinamide, or ethambutol. HIV status did not influence this result. Intermediate and rapid NAT2 genotypes were associated with lower isoniazid exposure. Pyrazinamide clearance increased with time on treatment, which was associated with lower serum pyrazinamide levels at the end of intensive phase of TB treatment. Ethambutol plasma concentrations were relatively low in our cohort of Tanzanian patients compared with previous studies, and older age was associated with lower clearance of ethambutol.

Supporting Information
S1 Protocol. Supplementary PDF file with the study protocol.

Acknowledgments
The authors would like to thank the health staff and study participants involved in the study. Special thanks go to Oswald Kaswamila, Lucy Magawa, and David Madili of the National Institute for Medical Research in Mwanza for excellent laboratory and clinical work assistance. The authors also acknowledge the contribution of Wynand Smythe at the University of Cape Town, who provided the prior values to support the PK model of ethambutol. The University of Cape Town analytical lab that performed that drug quantification assay was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI106701. The Division of Clinical Pharmacology at the University of Cape Town acknowledge Novartis Pharma for their support of the development of pharmacometrics skills in Africa.

Author Contributions
Conceived and designed the experiments: ABA NR HF HM JC. Performed the experiments: KJ GP LW SC DFJ EC PD CMH MC. Analyzed the data: KJ PD DFJ. Wrote the paper: KJ PD. Contributed to interpretation of the results and comments on drafts and approved the final version: ABA NR HF HM KJ GP LW SC DFJ EC JC PD MC CMH.

References
1. Wada M, Yoshiyama T, Ogata H, Ito K, Mizutani S, Sugita H. [Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis—six year experiences on its effectiveness, toxicity, and acceptability]. Kekkaku. 1999; 74(4):353–60. Epub 1999/06/04. PMID: 10355221.
2. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society. Monaldi Arch Chest Dis. 49(4):327–45. Epub 1994/09/01. PMID: 8000420.
3. Fattorini L, Piccaro G, Mustazzolu A, Giannoni F. Targeting Dormant Bacilli to Fight Tuberculosis. Medit J Hematol Infect Dis. 2013; 5(1):e2013072. Epub 2013/12/24. doi: 10.4084/mjhid.2013.072 PMID: 24363887; PubMed Central PMCID: PMCPMC3867226.

4. World Health Organization. Global tuberculosis report 2013. Geneva, Switzerland: World Health Organization; 2013.

5. Ministry of Health and Social welfare. Manual of the national tuberculosis and leprosy programme in Tanzania Dar es Salaam: 2013 [cited 2014 30 November]. Sixth:Available from:ntlp.go.tz/index.php?option=com_phocadownload&view...
21. NACP. National AIDS Control Programme (NACP) National Guidelines For the Management of HIV and AIDS, Government of Tanzania. 2009.

22. Beal S, Sheiner L., Boeckmann A., & Bauer R. (NONMEM users guides (1989–2009). Ellicott City, MD, USA.: ICON Development Solution; 2009.

23. Keizer RJ, Karlsson MO, Hooker A. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT: pharmacometrics & systems pharmacology. 2013; 2:e50. Epub 2013/07/10. doi: 10.1038/sp.2013.24 PMID: 23836189; PubMed Central PMCID: PMCPMC3697037.

24. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007; 34(5):711–27. Epub 2007/07/27. doi: 10.1007/s10928-007-9066-0 PMID: 17653836.

25. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008; 48:303–32. Epub 2007/10/05. doi: 10.1146/annurev.pharm tox.48.113006.094708 PMID: 17914927.

26. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. The AAPS journal. 2009; 11(3):558–69. Epub 2008/08/04. doi: 10.1208/s12248-009-9133-0 PMID: 19649712; PubMed Central PMCID: PMCPMC2758126.

27. Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. The AAPS journal. 2012; 14(3):601–11. Epub 2012/06/01. doi: 10.1208/s12248-012-9373-2 PMID: 22648902; PubMed Central PMCID: PMCPMC3385822.

28. Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002; 29(5–6):473–505. Epub 2003/06/11. PMID: 12795242.

29. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014; 371(17):1588–98. Epub 2014/10/23. doi: 10.1056/NEJMoa1315817 PMID: 25337748.

30. Karyadi E, West CE, Schultink W, Nelwan RH, Gross R, Amin Z, et al. A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status. Am J Clin Nutr. 2002; 75(4):720–7. Epub 2002/03/28. PMID: 11916759.

31. Ramakrishnan CV, Rajendran K, Jacob PG, Fox W, Radhakrishna S. The role of diet in the treatment of pulmonary tuberculosis. An evaluation in a controlled chemotherapy study in home and sanatorium patients in South India. Bull World Health Organ. 1961; 25:339–59. Epub 1961/01/01. PMID: 14490068; PubMed Central PMCID: PMCPMC555577.

32. Fritis H. Micronutrient interventions and HIV infection: a review of current evidence. Trop Med Int Health. 2006; 11(12):1849–57. Epub 2006/12/21. doi: 10.1111/j.1365-3156.2006.01740.x PMID: 17176350.

33. Tilak AV, Iyer SN, Mukherjee MS, Singhal RS, Lele SS. Full-gene-sequencing analysis of N-acetyltransferase-2 in an adult Indian population. Genetic testing and molecular biomarkers. 2013; 17(3):188–94. Epub 2012/12/12. doi: 10.1089/gtmb.2012.0258 PMID: 23216273.

34. Matimba A, Del-Faverio J, Van Broeckhoven C, Masimirembwa C. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Human genomics. 2009; 3(2):169–88. Epub 2009/04/09. doi: 10.1007/s12248-009-9133-0 PMID: 19649712; PubMed Central PMCID: PMCPMC2758126.

35. Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 genotypes on the plasma concentration of isoniazid and acetylsalicylic acid in Chinese pulmonary tuberculosis patients. Clin Chim Acta. 2006; 365(1–2):104–8. Epub 2005/09/27. doi: 10.1016/j.cca.2005.08.012 PMID: 16182272.

36. Chirehwa MR, R. Mthiyane, T. Onyebuoj, P. Smith, P. Mcilleron, H. & Dentl., Population pharmacokinetics of Pyrazinamide among HIV/TB co-infected patients at different levels of immunosuppression in South Africa. In World Congress of Pharmacology. 2014:(p. Poster 265). Cape Town, South Africa.

37. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003; 42(9):819–50. Epub 2003/07/29. doi: 10.2165/00003088-200342090-00003 PMID: 12882588.
40. Babalik A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildiz L, et al. Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients. Int J Tuberc Lung Dis. 2013; 17(11):1442–7. Epub 2013/10/16. doi:10.5588/ijtld.12.0771 PMID: 24125448.

41. Chigutsa E. Population pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of antitubercular drugs. University of Cape Town, SA University of Cape Town; 2013.

42. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother. 1999; 43(3):568–72. Epub 1999/02/27. PMID: 10049268; PubMed Central PMCID: PMCPMC89161.

43. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother. 1997; 41(12):2670–9. Epub 1998/01/07. PMID: 9420037; PubMed Central PMCID: PMCPMC164187.

44. Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, et al. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. Antimicrob Agents Chemother. 2013; 57(7):3208–13. Epub 2013/05/01. doi: 10.1128/aac.02599-12 PMID: 23629715; PubMed Central PMCID: PMCPMC3697325.

45. Fahimi F, Tabarsi P, Kobarfard F, Bozorg BD, Goodarzi A, Dastan F, et al. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013; 17(12):1602–6. Epub 2013/11/10. doi: 10.5588/ijtld.13.0019 PMID: 24200276.

46. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis. 2005; 41(4):461–9. Epub 2005/07/20. doi: 10.1086/431984 PMID: 16028152.

47. Um SW, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis. 2007; 11(9):972–8. Epub 2007/08/21. PMID: 17705974.

48. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest. 1998; 113(5):1178–83. Epub 1998/05/22. PMID: 9596291.

49. McIlleron H, Rustomejee R, Vahedi M, Mthiyane T, Denti P, Connolly C, et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012; 56(6):3232–8. Epub 2012/03/14. doi: 10.1128/aac.05526-11 PMID: 22411614; PubMed Central PMCID: PMCPMC3370773.

50. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy. 1998; 18(6):1205–11. Epub 1998/12/17. PMID: 9855317.

51. Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis. 2004; 8(11):1360–7. Epub 2004/12/08. PMID: 15581206.